The Asia Pacific In situ Hybridization Market is expected to witness a significant growth in the upcoming years. In situ hybridization (ISH) is a technique used to detect and localize mRNA and miRNA molecules in cells and tissues. This technique is used to study gene expression patterns, as well as to detect gene mutations and chromosomal abnormalities.
Currently, APAC In situ Hybridization Market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. The growth is largely driven by increasing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics.
The Asia Pacific In situ Hybridization Market is driven by factors such as the increasing prevalence of genetic disorders, technological advancements, and the increasing demand for personalized medicine. In addition, technological developments in the field of genomics are expected to fuel the growth of the market. The increasing demand for precision medicine and personalized treatments, as well as the increasing use of in situ hybridization for diagnostics and research purposes are also expected to drive the growth of the market.
The Asia Pacific In situ Hybridization Market is segmented on the basis of product, application, end-user, and region. By product, the market is segmented into reagents and kits, instruments, and software and services. By application, the market is segmented into diagnostic and research. By end-user, the market is segmented into hospitals, diagnostic centers, research and academic institutes, and biotechnology and pharmaceutical companies.
The major players in the Asia Pacific In situ Hybridization Market are Abbott Laboratories (US), Abcam (UK), Abnova Corporation (Taiwan), Agilent Technologies (US), Bio SB (US), Biocare Medical (US), BioGenex Laboratories (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), BioView (Israel), Danaher (US), Enzo Biochem (US), F. Hoffmann-La Roche (Switzerland), Merck (Germany), NeoGenomics Laboratories (US), OpGen (US), PerkinElmer (US), QIAGEN (Germany), Thermo Fisher Scientific (US), and ZytoVision (Germany).
Request for assumptions how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=51341505
Some of the prominent trends that the market is witnessing include increasing investments in research and development and increasing focus on precision medicine. The increasing demand for personalized treatments and the increasing use of in situ hybridization for diagnostics and research purposes are also expected to drive the growth of the market. Moreover, the technological advancements in the field of genomics and the increasing prevalence of genetic disorders are expected to drive the growth of the market.
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51341505
Recent Developments
- In 2022, RNAscope ISH Detection Kit manufactured by Bio-Techne received CE-IVD approval for the BOND-III platform (Leica Biosystems).
- In 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered a strategic commercial partnership granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.
- In 2020, Creative Bioarray introduced an advanced FISH probe to detect the 2019 Novel Coronavirus.
Content Source:
https://www.marketsandmarkets.com/Market-Reports/apac-in-situ-hybridization-market-51341505.html
